Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

@inproceedings{Yao2016EffectivenessAS,
  title={Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation},
  author={Xiaoxi Yao and Neena S. Abraham and Lindsey R. Sangaralingham and M Fernanda Bellolio and Robert McBane and Nilay D. Shah and Peter A. Noseworthy},
  booktitle={Journal of the American Heart Association},
  year={2016}
}
BACKGROUND The introduction of non-vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice. We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin. METHODS AND RESULTS Using a large US insurance database, we identified privately insured and Medicare Advantage patients with… CONTINUE READING